We were all rocked by the dismissal of Dr Mikovits from the WPI last September. Next she was arrested, and then we heard that the VIPDx tests, costing some $550 a throw, were worthless. Did this mean the whole XMRV story was false? What was the politics behind it all? What connection was there between the WPI, VIPDx, and Lombardi, how was Dr Judy involved, and what was behind the sacking? Were those paid-for tests really a waste of time? This is from an article by ME Advocacy.
Since September 2011, I along with several of my friends, who also have ME, have been left feeling battered by the events surrounding the ME retroviruses. Although other labs had avoided use of the methods from Lombardi et al. for nearly two years, the blood study and testing at VIP Dx, was a promise to patients that science was finally going to take over control of this disease. But on the 3rd October 2011, on reading that Annette Whittemore had closed the WPI research program, everything felt like it had fallen apart. In all honesty the emotion on that day was nothing compared to how I felt on reading that Dr Judy Mikovits had been arrested.
I have tried to gather every bit of information I could find to work out what has been going on. Most of what follows will raise more questions than answers, but here's where I've got to so far. My questions are:
1) Were the tests sold to patients by REDLABS (trading under the name VIP Dx) clinically validated? Where is their analytical and clinical sensitivity data?
2) Why would the NIH invite REDLABS (trading as VIP Dx), an independent company with a vested interest, to take part in the Blood working group (BWG) without seeing their clinical validation data? Has the analytical and clinical sensitivity data been seen by Graham Simmons, Michael Busch or Steven Kleinman of the BWG? Why were the results of the REDLABS team lead by Dr Lombardi not published in the BWG paper? This was the one chance to clinically validate the commercial REDLABS/VIP DX tests in the eyes of the world? Why was this chance not taken, what went wrong?
3) How did the trust set up by the Whittmore’s for their interests in REDLABS (trading as VIP Dx) operate, and how was the money generated by XMRV testing spent by the Whittmore’s?
Note: From now on I will refer to VIP Dx as REDLABS
Note: REDLABS USA Inc is not R.E.D. Laboratories in Belgium. The Belgian lab is not related to this presentation
PART 1: AN XMRV TEST FOR SALE
Lombardi et al. was published on the 8th October 2009 (1). It then took only 20 days for a commercial agreement to be reached between the WPI and REDLABS for XMRV tests to be sold to patients.
WPI Research Scientist and co-author of the Science paper, Dr Vincent Lombardi, is providing technical assistance and oversight of the VIP Dx testing. In exchange for the non-exclusive license, VIP Dx will pay a royalty to WPI for each test it conducts.
“We structured the licensing contract to be sure that any and all profits that might emerge at VIP Dx from XMRV testing come directly back to WPI to benefit the research program” said Whittemore.
As Annette Whittemore was President of the WPI (the non profit organization)(4), it means that she effectively entered into a licensing agreement with REDLABS, a company wholly controlled by her husband, Harvey Whittemore (5). REDLABS therefore had legal responsibility and liability for selling XMRV tests.
This does not mean that REDLABS and the WPI research laboratory were one in the same. They were completely separate physically and legally. The lead scientist at the WPI research lab, Dr Judy Mikovits, did not work for REDLABS and had no authority over testing or oversight at that clinical laboratory. As the principle investigator, Dr Mikovits would not supervise or monitor any activities taking place there. It was Dr Vincent Lombardi who was given responsibility for overseeing the testing at REDLABS and it was Dr Lombardi who was also instrumental in changing the methods used by REDLABS to methods not used in Lombardi et al. (3).
According to a WPI press release on the 14 January 2010 (3), Dr Vincent Lombardi was a WPI employee when he took up the responsibility of overseeing the XMRV testing at REDLABS. He was also said to have no personal financial interests in REDLABS, and that likewise the WPI family had put their interest in REDLABS into trust.
This begs two questions; did Dr Lombardi have any other kind of financial interest or position of power relating to REDLABS and what was the nature of the trust?
Dr Lombardi was in fact a co-founder of REDLABS. What we do not know is whether Dr Lombardi was ever or still is also a part owner of REDLABS.
Given the wording of the announcement (3) it may well be that Dr Lombardi was a trustee for the Whittemore family beneficial interest in REDLABS. This situation would mean that the Whittemores would effectively retain control of their beneficial interests in the trust, with Dr Lombardi was their employee, allowing them to retain control of the money and the way it was spent. Alternatively, the trustee could be a separate company under Whittemore control. The trustee could then approve monies in the Whittemore REDLABS trust account to be spent on any purpose that the Whittemores wanted.
At the very least, if there was no contrary stipulation in the trust, the Whittmores could spend money at WPI for any purpose. In effect it would mean that money accrued via XMRV testing could enter Whittemore owned bank accounts free of any tax liability or any stipulation on how the money could be spent. The wording in the press release also seems to suggest that the trust be set up for the benefit of WPI (not the WPI) and not specifically to be used for research.
Dr Lombardi was said to have "no personal financial interest" in REDLABS, trading as VIP Dx, by an official WPI press release (3). This is a legal description and should not be viewed as normal english. Not having a personal financial interest does not mean he does not have any financial interest in REDLABS/VIP Dx. Likewise, not having a personal financial interest does not mean that he is not a financially interested person (8). These are specific legal definitions.
If Dr Lombardi as an employee was also a trustee of the trust governing the beneficial interests of the Whittemore family in REDLABS, he would then have an organizational financial interest in REDLABS as opposed to a personal financial interest. Meaning that he would be a financially interested person with an organizational financial interest in REDLABS.
So was Dr Lombardi a trustee? Was Dr Lombardi a financially interested person? And what was the legal nature of that financial interest?
The motive for granting a licence to REDLABS can also be said to not have been as a result of “an overwhelming request for a diagnostic test for XMRV” (2), because negotiations between WPI and REDLABS were already underway prior to publication of Lombardi et al. on the 23rd October 2009 (9). Again, this does raise the question of how these methods were clinically validated?
With Dr Lombardi specifically being assigned to REDLABS, we must also ask whether he ever worked in the research lab after the publication of Lombardi et al. (2009) and why would he therefore be suitable to be the principle investigator on the NIH Research Project Grant (RO1) that Dr Mikovits had been originally been awarded? As operations manager of a commercial company he would be assumed to have a financial conflict of interest under NIH guidelines for principle investigators (10) and his professional research laboratory experience would be in question.
As I noted earlier, the initial licence for testing was for use of the methods employed in Lombardi et al. (2009). At some point Dr Lombardi was instrumental in altering the XMRV tests sold by REDLABS (11), but it has not been confirmed that these new methods were given a license or what data was available to validate these tests.
If there was no new data why were the methods used at REDLABS changed? Were the new methods even given a license? If the answer is yes, who approved the license? Were these new methods clinically validated? How were they validated and who approved the validation? It certainly wasn’t Dr Mikovits, because she had no ability to influence activities at REDLABS.
It was not an easy decision for patients to be tested for a retrovirus and most do not have the cash to spare. I think the entire ME community is entitled to answers to all of the outstanding questions regarding the validation, licensing, financial interests and trust arrangements between WPI, REDLABS and Dr Lombardi. Trust documents and the names of all the trustees should also be made publicly available.
[Please note that this article relates to the XMRV tests that were sold by REDLABS (trading as VIP Dx) and that UNEVX is another separate company unrelated to REDLABS, and that R.E.D Laboratories Belgium is not connected with the REDLABS owned by Harvey Whittemore]
PART 2: coming soon...
REFERENCES
1) Lombardi et al. 2009. Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome. Science. http://www.sciencemag.org/content/326/5952/585
2) Frankie Vigil, R&R Partners for Whittemore Peterson Institute, 28 October 2009. http://www.wpinstitute.org/news/docs/WPI Release Diagnostic Test.pdf
3) Frankie Vigil, R&R Partners for Whittemore Peterson Institute, 14 January 2010 http://wpinstitute.org/news/docs/WPI_pressrel_011410.pdf
4) Annette Whittemore profile, WPI President. http://www.wpinstitute.org/about/about_execboard.html
5) Harvey Whittemore, REDLABS USA INC. http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=3HqeF%2fFCg2b8fQKoGUKjpg%3d%3d
6) HIPAASpace NPI form: 1356473177 REDLABS USA INC http://www.hipaaspace.com/Medical_B..._Provider_Identifier/Codes/NPI_1356473177.pdf
7) Vincent C. Lombardi profile, WPI. http://www.wpinstitute.org/research/research_profiles.html
02x1: Financial Disclosure Issues Concerning Trustees, Executors, and Administrators. http://www.oge.gov/DisplayTemplates/ModelSub.aspx?id=1293
8) Lombardi et al., 2009. http://www.sciencemag.org/content/326/5952/585.full.pdf
NIH. Financial Conflict of Interest. http://grants.nih.gov/grants/policy/coi/tutorial/fcoi.pdf
9) Statement of Vincent Lombardi, Phd, Clinical Lab Director, VIP Dx, 14 October 2011. http://niceguidelines.blogspot.co.uk/2011/10/statement-by-vincent-lombardi.html
10) Dr Mikovits, 4 October 2011. http://news.sciencemag.org/scienceinsider/2011/10/xmrv-researcher-fired.html
11) Statement of Vincent Lombardi, Phd, Clinical Lab Director, VIP Dx, 14 October 2011. http://niceguidelines.blogspot.co.uk/2011/10/statement-by-vincent-lombardi.html
12) Dr Mikovits, 4 October 2011. http://news.sciencemag.org/scienceinsider/2011/10/xmrv-researcher-fired.html
XMRV testing: The REDLABS, trading as VIP Dx, WPI connection
Since September 2011, I along with several of my friends, who also have ME, have been left feeling battered by the events surrounding the ME retroviruses. Although other labs had avoided use of the methods from Lombardi et al. for nearly two years, the blood study and testing at VIP Dx, was a promise to patients that science was finally going to take over control of this disease. But on the 3rd October 2011, on reading that Annette Whittemore had closed the WPI research program, everything felt like it had fallen apart. In all honesty the emotion on that day was nothing compared to how I felt on reading that Dr Judy Mikovits had been arrested.
I have tried to gather every bit of information I could find to work out what has been going on. Most of what follows will raise more questions than answers, but here's where I've got to so far. My questions are:
1) Were the tests sold to patients by REDLABS (trading under the name VIP Dx) clinically validated? Where is their analytical and clinical sensitivity data?
2) Why would the NIH invite REDLABS (trading as VIP Dx), an independent company with a vested interest, to take part in the Blood working group (BWG) without seeing their clinical validation data? Has the analytical and clinical sensitivity data been seen by Graham Simmons, Michael Busch or Steven Kleinman of the BWG? Why were the results of the REDLABS team lead by Dr Lombardi not published in the BWG paper? This was the one chance to clinically validate the commercial REDLABS/VIP DX tests in the eyes of the world? Why was this chance not taken, what went wrong?
3) How did the trust set up by the Whittmore’s for their interests in REDLABS (trading as VIP Dx) operate, and how was the money generated by XMRV testing spent by the Whittmore’s?
Note: From now on I will refer to VIP Dx as REDLABS
Note: REDLABS USA Inc is not R.E.D. Laboratories in Belgium. The Belgian lab is not related to this presentation
PART 1: AN XMRV TEST FOR SALE
Lombardi et al. was published on the 8th October 2009 (1). It then took only 20 days for a commercial agreement to be reached between the WPI and REDLABS for XMRV tests to be sold to patients.
Note: this does not say clinically validated“In response to an overwhelming request for a diagnostic test for XMRV, WPI has temporarily agreed to allow Viral Immune Pathology Diagnostics (VIP Dx) to begin offering the identical tests that have been extensively validated using the same technology developed by Drs. Lombardi and Mikovits and their colleagues as reported in Science.”
(Frankie Vigil, R&R Partners for Whittemore Peterson Institute, 28 October 2009) (2)
WPI Research Scientist and co-author of the Science paper, Dr Vincent Lombardi, is providing technical assistance and oversight of the VIP Dx testing. In exchange for the non-exclusive license, VIP Dx will pay a royalty to WPI for each test it conducts.
“We structured the licensing contract to be sure that any and all profits that might emerge at VIP Dx from XMRV testing come directly back to WPI to benefit the research program” said Whittemore.
It is important to appreciate that just because research data is published, it does not mean that a test has been clinically validated. This type of validation would require samples from hundreds of healthy volunteers. So is it possible to do this kind of work in 20 days? If the Whittemore Peterson Institute laboratory research data is all that was published, what data was used to grant a licence? And who approved that licence? If the only data available were from Lombardi et al. (2009), then the tests would still need to be clinically validated."Dr. Lombardi is an employee of WPI, and has no personal financial interest in VIP Dx. Likewise, the Whittemore family put their interest in VIP Dx into a trust to benefit WPI. The availability of these tests has a dramatic impact to the CFS/ME community. These tests allow licensed laboratories to begin answering important questions about XMRV’s incidence in disease and prevalence in the world. WPI hopes that this will generate further research related to XMRV. "The institutes’ driving goal continues to be the translation of research to meaningful results for patients, explained Whittemore."
(Frankie Vigil, R&R Partners for Whittemore Peterson Institute, 14 January 2010) (3)
As Annette Whittemore was President of the WPI (the non profit organization)(4), it means that she effectively entered into a licensing agreement with REDLABS, a company wholly controlled by her husband, Harvey Whittemore (5). REDLABS therefore had legal responsibility and liability for selling XMRV tests.
2007
Provider (Organization) Full Name: REDLABS USA INC
Provider (Organization) Other Name: Viral Immune Pathology Diagnostics
(HIPAASpace NPI form: 1356473177 REDLABS USA INC) (6)
This does not mean that REDLABS and the WPI research laboratory were one in the same. They were completely separate physically and legally. The lead scientist at the WPI research lab, Dr Judy Mikovits, did not work for REDLABS and had no authority over testing or oversight at that clinical laboratory. As the principle investigator, Dr Mikovits would not supervise or monitor any activities taking place there. It was Dr Vincent Lombardi who was given responsibility for overseeing the testing at REDLABS and it was Dr Lombardi who was also instrumental in changing the methods used by REDLABS to methods not used in Lombardi et al. (3).
According to a WPI press release on the 14 January 2010 (3), Dr Vincent Lombardi was a WPI employee when he took up the responsibility of overseeing the XMRV testing at REDLABS. He was also said to have no personal financial interests in REDLABS, and that likewise the WPI family had put their interest in REDLABS into trust.
This begs two questions; did Dr Lombardi have any other kind of financial interest or position of power relating to REDLABS and what was the nature of the trust?
Dr Lombardi was in fact a co-founder of REDLABS. What we do not know is whether Dr Lombardi was ever or still is also a part owner of REDLABS.
“Prior to the completion of his graduate degree he co-founded the specialty clinical laboratory, Redlabs, U.S.A., Inc. This clinical laboratory, which later became VIPDx, was formed to serve doctors and their patients who suffer from CFS. Dr. Lombardi served as the Director of Operations as well as the leader of laboratory research and development for new diagnostics in the clinical laboratory.”
(Vincent C. Lombardi profile, WPI) (7)
Given the wording of the announcement (3) it may well be that Dr Lombardi was a trustee for the Whittemore family beneficial interest in REDLABS. This situation would mean that the Whittemores would effectively retain control of their beneficial interests in the trust, with Dr Lombardi was their employee, allowing them to retain control of the money and the way it was spent. Alternatively, the trustee could be a separate company under Whittemore control. The trustee could then approve monies in the Whittemore REDLABS trust account to be spent on any purpose that the Whittemores wanted.
At the very least, if there was no contrary stipulation in the trust, the Whittmores could spend money at WPI for any purpose. In effect it would mean that money accrued via XMRV testing could enter Whittemore owned bank accounts free of any tax liability or any stipulation on how the money could be spent. The wording in the press release also seems to suggest that the trust be set up for the benefit of WPI (not the WPI) and not specifically to be used for research.
Dr Lombardi was said to have "no personal financial interest" in REDLABS, trading as VIP Dx, by an official WPI press release (3). This is a legal description and should not be viewed as normal english. Not having a personal financial interest does not mean he does not have any financial interest in REDLABS/VIP Dx. Likewise, not having a personal financial interest does not mean that he is not a financially interested person (8). These are specific legal definitions.
If Dr Lombardi as an employee was also a trustee of the trust governing the beneficial interests of the Whittemore family in REDLABS, he would then have an organizational financial interest in REDLABS as opposed to a personal financial interest. Meaning that he would be a financially interested person with an organizational financial interest in REDLABS.
So was Dr Lombardi a trustee? Was Dr Lombardi a financially interested person? And what was the legal nature of that financial interest?
The motive for granting a licence to REDLABS can also be said to not have been as a result of “an overwhelming request for a diagnostic test for XMRV” (2), because negotiations between WPI and REDLABS were already underway prior to publication of Lombardi et al. on the 23rd October 2009 (9). Again, this does raise the question of how these methods were clinically validated?
“Note added in proof: V.C.L. is operations manager of Viral Immune Pathologies Laboratory, which is in negotiations with the Whittemore Peterson Institute to offer a diagnostic test for XMRV.”
(Lombardi et al. 2009) (9)
With Dr Lombardi specifically being assigned to REDLABS, we must also ask whether he ever worked in the research lab after the publication of Lombardi et al. (2009) and why would he therefore be suitable to be the principle investigator on the NIH Research Project Grant (RO1) that Dr Mikovits had been originally been awarded? As operations manager of a commercial company he would be assumed to have a financial conflict of interest under NIH guidelines for principle investigators (10) and his professional research laboratory experience would be in question.
As I noted earlier, the initial licence for testing was for use of the methods employed in Lombardi et al. (2009). At some point Dr Lombardi was instrumental in altering the XMRV tests sold by REDLABS (11), but it has not been confirmed that these new methods were given a license or what data was available to validate these tests.
“The “XMRV test” offered by VIP Dx is clinically validated and performed under rigorous protocols to ensure the accuracy and reliability of the test results. XMRV testing was offered based upon the existing scientific knowledge at the time. The original assays for XMRV testing were based on the 2009 Science publication. Those assays, as well as all subsequent modifications, were internally validated prior to being used to process patients’ samples.“
(Statement of Vincent Lombardi, Phd, Clinical Lab Director, VIP Dx, 14 October 2011) (11)
If there was no new data why were the methods used at REDLABS changed? Were the new methods even given a license? If the answer is yes, who approved the license? Were these new methods clinically validated? How were they validated and who approved the validation? It certainly wasn’t Dr Mikovits, because she had no ability to influence activities at REDLABS.
"I've asked them for the better part of 2 years to show me that what we got in Lombardi et al. is the same thing they're selling to patients."
(Dr Mikovits, 4 October 2011) (12)
It was not an easy decision for patients to be tested for a retrovirus and most do not have the cash to spare. I think the entire ME community is entitled to answers to all of the outstanding questions regarding the validation, licensing, financial interests and trust arrangements between WPI, REDLABS and Dr Lombardi. Trust documents and the names of all the trustees should also be made publicly available.
[Please note that this article relates to the XMRV tests that were sold by REDLABS (trading as VIP Dx) and that UNEVX is another separate company unrelated to REDLABS, and that R.E.D Laboratories Belgium is not connected with the REDLABS owned by Harvey Whittemore]
PART 2: coming soon...
REFERENCES
1) Lombardi et al. 2009. Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome. Science. http://www.sciencemag.org/content/326/5952/585
2) Frankie Vigil, R&R Partners for Whittemore Peterson Institute, 28 October 2009. http://www.wpinstitute.org/news/docs/WPI Release Diagnostic Test.pdf
3) Frankie Vigil, R&R Partners for Whittemore Peterson Institute, 14 January 2010 http://wpinstitute.org/news/docs/WPI_pressrel_011410.pdf
4) Annette Whittemore profile, WPI President. http://www.wpinstitute.org/about/about_execboard.html
5) Harvey Whittemore, REDLABS USA INC. http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=3HqeF%2fFCg2b8fQKoGUKjpg%3d%3d
6) HIPAASpace NPI form: 1356473177 REDLABS USA INC http://www.hipaaspace.com/Medical_B..._Provider_Identifier/Codes/NPI_1356473177.pdf
7) Vincent C. Lombardi profile, WPI. http://www.wpinstitute.org/research/research_profiles.html
02x1: Financial Disclosure Issues Concerning Trustees, Executors, and Administrators. http://www.oge.gov/DisplayTemplates/ModelSub.aspx?id=1293
8) Lombardi et al., 2009. http://www.sciencemag.org/content/326/5952/585.full.pdf
NIH. Financial Conflict of Interest. http://grants.nih.gov/grants/policy/coi/tutorial/fcoi.pdf
9) Statement of Vincent Lombardi, Phd, Clinical Lab Director, VIP Dx, 14 October 2011. http://niceguidelines.blogspot.co.uk/2011/10/statement-by-vincent-lombardi.html
10) Dr Mikovits, 4 October 2011. http://news.sciencemag.org/scienceinsider/2011/10/xmrv-researcher-fired.html
11) Statement of Vincent Lombardi, Phd, Clinical Lab Director, VIP Dx, 14 October 2011. http://niceguidelines.blogspot.co.uk/2011/10/statement-by-vincent-lombardi.html
12) Dr Mikovits, 4 October 2011. http://news.sciencemag.org/scienceinsider/2011/10/xmrv-researcher-fired.html